Veenat 400mg Tablet

• Chronic Myeloid Leukemia (CML)
• Acute Lymphocytic Leukemia (ALL)
• Gastrointestinal Stromal Tumors (GIST)
• Myelodysplastic/Myeloproliferative Diseases (MDS/MPD)
• Hypereosinophilic Syndrome (HES)
• Chronic Eosinophilic Leukaemia (CEL)
• Dermatofibrosarcoma Protuberans (DFSP)

Side effects of Veenat are as follows:

Common Side Effects:

• Fatigue, tiredness, or weakness
  
• Headache and dizziness
  
• Nausea, vomiting, diarrhea, or abdominal pain
  
• Fever, cough, or breathing difficulties
  
• Rash, skin changes, or night sweats
  
• Muscle cramps, joint or bone pain
  
• Swelling in the face, legs, ankles, or feet (edema)
  
• Weight gain
  
• Trouble sleeping (insomnia)
  
• Dry eyes or nasal inflammation
  
• Changes in blood counts (low red and white blood cells)
  
  Serious Side Effects:
  
• Heart failure or abnormal heart rhythms
  
• Liver problems, including liver failure
  
• Gastrointestinal disorders
  
• Hypothyroidism
  
• Severe allergic reactions
  
• Generalized swelling in the body

• Take Veenat 400mg Tablet as prescribed by your doctor.
• Do not crush or chew. Swallow it as a whole tablet with a glass of water.
• Do not take this medicine on an empty stomach. Take this tablet with or after food.
  
  

Veenat 400 Tablet (Imatinib) is an anti-cancer medication. A protein enzyme, bcr-abl tyrosine kinase, responsible for the growth of abnormal proliferation of cancer cells. This medicine inhibits the proliferation and induces apoptosis (planned cell death) in bcr-abl positive cells (cancer cells). This is how it works to stop or slow the spread of cancer.

In case you miss your dose of Veenat 400 Tablet, skip that dose but resume the regular dosage routine. You should never take double doses.

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices—plus special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.


We currently ship to:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.
Experience the quality everyone’s talking about – order today!

• Arora, R., Sharma, M., Monif, T., & Iyer, S. (2024). A multi‑centric bioequivalence trial in Ph+ chronic myeloid leukemia patients to assess bioequivalence and safety evaluation of generic imatinib mesylate 400 mg tablets. Cancer Research and Treatment, 48(3), 1120–1129 - https://pubmed.ncbi.nlm.nih.gov/26875198/
• Generic Imatinib–Free Trial‑in‑CML–Chronic Phase Study. (2023). Indian Journal of Medical Research. Feasibility of treatment‑free remission with generic imatinib in chronic‑phase CML.
• Ghadyalpatil, N., Banawali, S., Kurkure, P., Arora, B., Bansal, S., Amare, P., Choughule, A., Soy, L., & Singh, R. (2023). Efficacy and tolerability of imatinib mesylate in pediatric chronic myeloid leukemia in a large cohort: Results from a tertiary care referral center in India. Journal of Clinical Oncology, 27(15-100), 10047 -https://ascopubs.org/doi/10.1200/jco.2009.27.15_suppl.10047
• Monitoring of response to therapy with imatinib mesylate in chronic myeloid leukemia in chronic phase (CML‑CP). (2024). Retrospective analysis showing comparable clinical and molecular outcomes with Veenat vs. Gleevec® - https://pmc.ncbi.nlm.nih.gov/articles/PMC4223192/
• Srivastava, S., & Dutt, S. (2023). Imatinib mesylate resistance and mutations: An Indian experience. Indian Journal of Medical and Paediatric Oncology, 34(3), 213–220 - https://pmc.ncbi.nlm.nih.gov/articles/PMC3902630/
• The cancer (2025). Monitoring of disease activity in CML‑CP patients treated with Indian generic Veenat (Natco) imatinib mesylate: A tertiary care experience. Cancer Translational Medicine, 1(2).